References
- Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006; 24(5):363–73.
- Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002;46(4):626–36.
- Ye S, Chen XX, Lu XY, Wu MF, Deng Y, Huang WQ, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26(10):1647–54.
- Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136(5):1341–7.
- Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713–9.
- Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563–70.
- Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012;51(5):800–4.
- Muro Y, Sugiura K, Akiyama M. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol. 2013;32(3):395–8.
- Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64(10):1602–10.
- Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21:245–53.
- Tristano AG. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit. 2008;14(8):RA27–36.
- World Medical Association Declaration of Helsinki. Available from: http://www.wma.net/en/30publications/10policies/b3/ [accessed 22 March 2013].
- Ethical Guidelines for Epidemiological Research. Available from: http://www.lifescience.mext.go.jp/files/pdf/n796_01.pdf [accessed 22 March 2013].
- Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.
- Sun WC, Sun YC, Lin H, Yan B, Shi GX. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol. 2012;167(6):1236–44.
- Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuo O, Nureki S, et al. Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol. 2007; 26(3):436–9.
- Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38(2–3):189–97.
- Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep. 2012;14(3):264–74.
- Nagasaka K, Harigai M, Tateishi M, Hara M, Yoshizawa Y, Koike T, et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol. 2003;13(3):231–8.